Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Peficitinib is an inhibitor of JAK (IC50s = 3.9, 5, and 0.71 nM for JAK1-3, respectively).1 It is 14-fold selective for JAK1 and JAK3 over JAK2 in erythropoietin-induced leukemia cell proliferation assays. Peficitinib inhibits IL-2-induced proliferation of rat splenocytes (IC50 = 10 nM) and phosphorylation of STAT5 in rat and human whole blood (IC50s = 124 and 127 nM, respectively).2 In vivo, peficitinib reduces paw swelling (ED50 = 5.6 mg/kg) and bone destruction in a rat model of adjuvant-induced arthritis when administered at a dose of 30 mg/kg.
WARNING This product is not for human or veterinary use.
1. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin. Investig. Drugs 23(8), 1067-1077 (2014).
2. A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-